TGNA News and Press, TEGNA Inc From 04/25/24

SEATTLE KRAKEN INCREASES BROADCAST AND STREAMING ACCESS THROUGH PARTNERSHIPS WITH TEGNA AND PRIME VIDEO PR Newswire Groundbreaking deal includes TEGNA stations in Seattle , Portland & Spokane and streaming on Prime Video across Washington , Oregon a...

Strasbourg, France, April 24, 2024, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined General Meeting (ordinary and extraordinary sessions) of Transgene’s shar...

Shareholders of TEGNA Inc. (NYSE: TGNA) today overwhelmingly approved the re-election of nine Board members and an advisory resolution on the compensation of the company’s named executive officers. TEGNA shareholders re-elected Board Chairman Howard D. Elias, president and CEO Dave Lou...

The Indiana Fever and TEGNA have announced an agreement to air select Fever games for free on WTHR and WALV in Indianapolis The announcement follows on the heels of the Fever’s historic 2024 draft and a renewed excitement by fans across the basketball world for the Fever, one o...

GREENWICH, Conn., April 22, 2024 (GLOBE NEWSWIRE) -- Gabelli Funds will host its 16 th Annual Media & Entertainment Symposium at the Harvard Club in New York City on Thursday, June 6, 2024. The symposium will feature discussions with leading companies and organizations across the media ec...

2024-04-15 02:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-10 10:11:36 ET Summary Entravision Communications' stock has dropped about 50% due to the loss of their contract with Meta Platforms. The company has invested around $100 million in digital M&A, but digital margins have been shrinking. The value of Entravision's TV...

Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers. All treated patients remain disease-free after a median follow-up of 18.6 months. Phase II part of the trial to start enrolling patients in coming weeks. ...

2024-04-03 02:21:05 ET Summary TEGNA has announced a capital allocation strategy to boost performance, including a $800 million share repurchase program and a 20% increase in dividends. The company has renewed its contractual obligations, focusing on content generation, customer e...

2023 Full-year results and business update Lead program TG4050 to deliver data in 2024. Advancements in other clinical programs and Research and Innovation (R&I) activity to deliver news flow and fuel growth in Transgene’s portfolio over the next 24 month...